Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
Lee Steven Schwartzberg
No relevant relationships to disclose
Fernando Rivera
Research Funding - Amgen
Meinolf Karthaus
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Gianpiero Fasola
Consultant or Advisory Role - Amgen
Honoraria - Merck
Jean-Luc Canon
Research Funding - Amgen
Hua Yu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen